Dopamine agonists in Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 8, Issue 4, 2008, Pages 671-677

  Yamamoto, Mitsutoshi ^b   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Cardiac valve fibrosis; Depression; Dopamine agonist; Motor complication; Neuroprotection; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SERTRALINE;

BRAIN DYSFUNCTION; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FIBROSIS; HALLUCINOSIS; HEART DISEASE; HUMAN; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PLEURAL FIBROSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIPARKINSON AGENTS; DEPRESSION; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 42249101380     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.4.671     Document Type: Review

References (65)

1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245 (2006).
2. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125, 861-870 (2002).
3. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease. Mov. Disord. 20, 523-539 (2005).
4. Pahwa R, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia [an evidence-based review]: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66, 983-995 (2006).
5. Olanow CW. Single blind double observer-controlled study of arbidopa/levodopa vs bromocriptine in untreated Parkinson patients. Arch. Neurol. 45, 205 (1988).
6. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 278, 125-130 (1997).
7. Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 49, 393-399 (1997).
8. Barone P, Bravi D, Bermejo-Pareja F et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 53, 573-579 (1999).
9. Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson's disease. Neurology 35, 199-206 (1985).
10. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 53, 364-370 (1999).
11. Rinne UK, Bracco F, Chouza C et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48, 363-368 (1997).
12. Rinne UK, Bracco F, Chouza C et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl. 1), 23-30 (1998).
13. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 49, 724-728 (1997).
14. Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, vd Burg W, Lakke JP. Low-dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled study. Neurology 36, 291-293 (1986).
15. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 35, 291-295 (1985).
16. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 49, 1060-1065 (1997).
17. Inzelberg R, Nisipeanu P, Rabey JM et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 47, 785-788 (1996).
18. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49, 162-168 (1997).
19. Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 51, 1057-1062 (1998).
20. Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov. Disord. 9, 40-47 (1994).
21. Toyokura Y, Mizuno Y, Kase M, Sobue I et al. Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study. Acta Neurol. Scand. 72, 157-170 (1985).
22. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol. 64(5), 676-682 (2007).
23. Poewe WH, Rascol O, Quinn N et al.; on behalf of the SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6(6), 513-520 (2007).
24. Schapira AH. Excessive daytime sleepiness in Parkinson's disease. Neurology 63, S24-S27 (2004).
25. Peralta C, Wolf E, Alber H et al. Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study. Mov. Disord. 21, 1109-1113 (2006).
26. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67, 1225-1229 (2006).
27. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356(1), 39-46 (2007).
28. Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342, 1484-1491 (2000).
29. Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61, 1044-1053 (2004).
30. Schapira AHV, Olanow CW. The medical management of Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AH, Olanow CW (Eds). Butterworth Heinemann, PA, USA, 119-143 (2006).
31. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, S2-S7 (2000).
32. Damiano AM, McGrath MM, Willian MK et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual. Life Res. 9, 87-100 (2000).
33. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41, 202-205 (1991).
34. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23, S117-S126 (2000).
35. Fahn S, Oakes D, Shoulson I, Kieburtz K et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351, 2498-2508 (2004).
36. Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58, S1-S8 (2002).
37. Oertel WH, Wolters E, Sampaio C et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. 21, 343-353 (2006).
38. Schapira AH. Treatment options in the modern management of Parkinson's disease. Arch. Neurol. 64, 1083-1088 (2007).
39. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety 11, 58-65 (2000).
40. Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J. Neurol. 253, 601-607 (2006).
41. Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J. Neurol. Sci. 248, 266-270 (2006).
42. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin. Neuropharmacol. 26, 109-111 (2003).
43. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 303, 791-804 (2002).
44. Schapira AH. Science, medicine, and the future: Parkinson's disease. BMJ 318, 311-314 (1999).
45. Schapira AH. Disease modification in Parkinson's disease. Lancet Neurol. 3, 362-368 (2004).
46. Ravina BM, Fagan SC, Hart RG et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60, 1234-1240 (2003).
47. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44, S167-S174 (1998).
48. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J. Neural. Transm. 104, 209-228 (1997).
49. Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71, 295-301 (1998).
50. Takashima H, Tsujihata M, Kishikawa M, Freed WJ. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D2receptors. Exp. Neurol. 159, 98-104 (1999).
51. Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91, 1075-1081 (2004).
52. Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch. Int. Pharmacodyn. Ther. 329, 221-230 (1995).
53. Ferger B, Teismann P, Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res. 883, 216-223 (2000).
54. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838, 51-59 (1999).
55. Ogawa N, Tanaka K, Asanuma M et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657, 207-213 (1994).
56. Opacka-Juffry J, Wilson AW, Blunt SB. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res. 810, 27-33 (1998).
57. Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 96, 1315-1321 (2006).
58. Parkinson Disease Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653-1661 (2002).
59. Whone AL, Watts RL, Stoessl AJ. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54, 93-101 (2003).
60. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease JAMA 291, 358-364 (2004).
61. Marek K, Jennings D, Tabamo R, Seibyl J. InSPECT: an investigation of the effect of short-term treatment with pramipexole or levodopa on [123I] B-CIT and SPECT imaging in early Parkinson disease. Neurology 66, A112 (2006)
62. Hilker R, Schweitzer K, Coburger S et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol. 62, 378-382 (2005).
63. Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541-1550 (2002).
64. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol. 59, 559-562 (2006).
65. Schapira AH, Bezard E, Brotchie J et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 5, 845-854 (2006).